Abstract:Candida auris is a serious health concern of the current world that possesses a serious global health threat and is emerging at a high rate. Available antifungal drugs are failing to combat this pathogen as they are growing resistant to those drugs and some strains have already shown resistance to all three available antifungal drugs in the market. Hence, finding alternative therapies is essential for saving lives from this enemy. To make the development of new treatments easier, we conducted some in silico study of this pathogen to discover possible targets for drug design and also recommended some possible metabolites to test in vivo circumstances. The complete proteome of the representative strain was retrieved, and the duplicate, non-essential, human homologous, non-metabolic, and druggable proteins were then eliminated. As a result, out of a total of 5441 C. auris proteins, we were able to isolate three proteins (XP 028890156.1, XP 028891672.1, and XP 028891858.1) that are crucial for the pathogen's survival as well as host-non-homolog, metabolic, and unrelated proteins to the human microbiome. Their subcellular locations and interactions with a large number of proteins (10 proteins) further point to them being good candidates for therapeutic targets. Following in silico docking of 29 putative antifungals of plant origin against the three proteins we chose, Caledonixanthone E, Viniferin, Glaucine, and Jatrorrhizine were discovered to be the most effective means of inhibiting those proteins since they displayed higher binding affinities (ranging from -28.97 kcal/mol to -51.99 kcal/mol) than the control fluconazole (which ranged between -28.84 kcal/mol and -41.15 kcal/mol). According to the results of MD simulations and MM-PBSA calculations, Viniferin and Caledonixanthone E are the most effective ligands for the proteins XP 028890156.1, XP 028891672.1, and XP 028891858.1. Furthermore, they were predicted to be safe and also showed proper ADME properties.

Discovery of a New Chemical Scaffold for the Treatment of Superbug Candida Auris Infections

Exploring the antifungal potential of novel carbazate derivatives as promising drug candidates against emerging superbug, Candida auris

New generation modified azole antifungals against multidrug-resistant Candida auris

Discovery of Novel α,β-Unsaturated Amide Derivatives as Candidate Antifungals to Overcome Fungal Resistance

Discovery of Piperidol Derivatives for Combinational Treatment of Azole-Resistant Candidiasis

Small molecule inhibitors of fungal Δ(9) fatty acid desaturase as antifungal agents against Candida auris

Inhibition of apoptosis and biofilm formation in Candida auris by click-synthesized triazole-bridged quinoline derivatives

Design, synthesis and in vitro biological studies of novel triazoles with potent and broad-spectrum antifungal activity

Synergistic Combinations of Antifungals and Anti-Virulence Agents to Fight Againstcandida Albicans

Discovery of highly potent triazoleantifungal agents with piperidine-oxadiazole side chains

Synthesis and antifungal evaluation of novel triazole derivatives bearing a pyrazole-methoxyl moiety

Discovery of novel purinylthiazolylethanone derivatives as anti-Candida albicans agents through possible multifaceted mechanisms

Subtractive proteomics analysis to uncover the potent drug targets for distinctive drug design of Candidaauris

Discovery and optimization of tetrahydroacridine derivatives as a novel class of antibiotics against multidrug-resistant Gram-positive pathogens by targeting type I signal peptidase and disrupting bacterial membrane

Discovery of Simplified Sampangine Derivatives As Novel Fungal Biofilm Inhibitors.

Current Perspectives of Antifungal Therapy: A Special Focus on Candida auris

Improved efficacy of antifungal drugs in combination with monoterpene phenols against Candida auris

Discovery of New Imidazole Derivatives Containing the 2,4-Dienone Motif with Broad-Spectrum Antifungal and Antibacterial Activity

Construction and Evaluation of Novel Dual-function Antifungal Inhibitors and Covalent Organic Framework Carriers Based on the Infection Microenvironment.

MBX-7591: a promising drug candidate against drug-resistant fungal infections

Beauvericin Counteracted Multi-Drug Resistant Candida Albicans by Blocking ABC Transporters